BridgeBio Pharma (BBIO) Intangibles (2018 - 2026)

BridgeBio Pharma (BBIO) has 8 years of Intangibles data on file, last reported at $27.4 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 1.59% year-over-year to $27.4 million; the trailing twelve-month figure through Mar 2026 stood at $27.4 million (down 1.59% YoY), and the FY2025 full-year result was $28.1 million, up 17.35% from the prior year.
• Intangibles retreated to $27.4 million in Q1 2026, from $28.1 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $30.5 million in Q1 2022 to a low of $23.9 million in Q4 2024.
• A 5-year average of $27.5 million and a median of $27.8 million in 2025 frame the typical range for Intangibles.
• Peak annual rise in Intangibles reached 91.41% in 2022, while the deepest fall reached 36.56% in 2022.
• Tracing BBIO's Intangibles over 5 years: stood at $28.7 million in 2022, then declined by 8.33% to $26.3 million in 2023, then slipped by 9.09% to $23.9 million in 2024, then gained by 17.35% to $28.1 million in 2025, then declined by 2.56% to $27.4 million in 2026.
• Business Quant data shows BBIO's Intangibles at $27.4 million in Q1 2026, $28.1 million in Q4 2025, and $28.8 million in Q3 2025.